PE-22-28

PE-22-28 is a synthetic antidepressant peptide derived from spadin, a naturally occurring peptide. Spadin itself (also called PE 12-28) is a fragment of the propeptide generated when the sortilin receptor, also known as neurotensin receptor-3 (NTSR3), is matured by the protease furin; spadin acts as a specific blocker of the TREK-1 two-pore-domain potassium channel and was identified as the first natural antidepressant peptide ^[2][4]. PE-22-28 is a shortened seven amino acid analog, corresponding to residues 22 to 28 of the propeptide, engineered from spadin's blood degradation products to improve stability and drug-like properties ^[1].

The biological premise is striking. TREK-1 is a potassium channel expressed in mood-relevant circuits that normally dampens serotonergic signaling; mice genetically lacking TREK-1 display a depression-resistant phenotype that mimics antidepressant treatment, so pharmacologically blocking the channel reproduces that resilient state ^[2]. Spadin validated this concept, binding TREK-1 with roughly 10 nM affinity, increasing the firing of serotonin neurons in the dorsal raphe, and producing antidepressant effects with a rapid onset, along with enhanced hippocampal neurogenesis and CREB phosphorylation after only a few days of treatment ^[2].

PE-22-28 was designed to be a superior, more practical version of spadin. In studies on human TREK-1 expressed in cells, PE-22-28 displayed far better specificity and affinity for the channel than spadin, and in behavioral models of depression such as the forced swimming and novelty-suppressed feeding tests it produced significant antidepressant-like effects; it also induced neurogenesis and enhanced synaptogenesis after short treatment, with a markedly longer duration of action than spadin ^[1]. Mechanistic work on spadin further showed activation of MAPK and PI3K signaling and increased expression of BDNF and synaptic proteins ^[3].

PE-22-28 is an investigational research peptide and is not an approved medication. Its evidence base is preclinical but mechanistically rich and internally consistent, and it is frequently highlighted as a fast-acting, novel-mechanism candidate that could offer an alternative to spadin in the treatment of depression ^[1].

Being straight with you, there is no human safety data for PE-22-28; every efficacy and tolerability signal comes from rodents, where it looked clean and, unlike broad TREK-1 blockade might suggest on paper, did not throw obvious cardiac or seizure trouble in those studies. It is an early stage research compound sold for research, not an approved medicine, so purity, dosing, and long term risk are all unsettled. In self experiment reports the gripes are minor: mild injection site irritation, occasional headache, and a little fatigue. It reads as a promising frontier mood tool rather than a proven therapy, and a solid neurogenic option to reach for in the mood peptide lane.

PE-22-28 descends from spadin, a naturally occurring peptide fragment shown to block the TREK-1 potassium channel, discovered by Marc Borsotto, Jean Mazella, Catherine Heurteaux and colleagues at the Institut de Pharmacologie Moleculaire et Cellulaire (CNRS) at the Universite Cote d'Azur in France around 2010. Because spadin's antidepressant activity faded within about seven hours of administration, the same team studied its blood breakdown products and designed a shortened, stabilized seven-amino-acid analog, PE-22-28, reported in 2017 ^[1]. In patch-clamp testing the new peptide inhibited human TREK-1 far more potently than spadin and produced antidepressant-like effects, along with neurogenesis and synaptogenesis, in rodent models. The compound remains a preclinical research peptide.

PE-22-28 is regarded as one of the more exciting frontier tools in the mood space because it acts through a genuinely novel mechanism, blocking the TREK-1 channel rather than manipulating monoamine reuptake like conventional antidepressants. Researchers find it compelling that animals bred to lack TREK-1 are naturally resistant to depression, giving the target strong biological rationale, and that the engineered peptide produced antidepressant-like behavior within days while promoting fresh neuronal and synaptic growth. Its dramatically improved potency and duration over spadin add to the appeal. The essential honest caveat is that all of this evidence is preclinical, drawn from cell and rodent studies, with no human clinical data yet available.